CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Merck KGaA

MKKGY
$65.78BLarge Cap

Next catalyst

Phase 3November 2026

Avelumab

Carcinoma, Hepatocellular

Get an email about MKKGY's next catalysts

Track Merck KGaA (MKKGY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 3 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

4 upcoming, 1 past

Phase 3Next

Avelumab Phase 3 Est. Readout

November 2026~Avelumab205

Estimated primary completion for Avelumab trial (NCT03815643) in Solid Tumors. Topline data typically follows completion by weeks to months.

Source
Phase 2

Bintrafusp alfa Phase 2 Est. Readout (TRUST)

January 2027~Bintrafusp alfa80

Estimated primary completion for Bintrafusp alfa trial (NCT04874311) in Advanced Soft-tissue Sarcoma. Topline data typically follows completion by weeks to months.

Source
Phase 3

Cetrorelix acetate Phase 3 Est. Readout

Q3 2027~QCetrorelix acetate266

Estimated primary completion for Cetrorelix acetate trial (NCT07340827) in Infertility. Topline data typically follows completion by weeks to months.

Source
Phase 2

Mirdametinib Phase 2 Est. Readout

Q4 2027~QMirdametinib24

Estimated primary completion for Mirdametinib trial (NCT06159166) in NF1. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

XetraPharmaceutical Preparations🇩🇪EuropeDarmstadt62.1K employees
Drug Pipeline

Single low dose cyclophosphamide

Phase 3

Non-small Cell Lung Cancer

Bintrafusp alfa

Phase 3

Advanced Soft-tissue Sarcoma

F0434

Phase 3

Diabetic Neuropathies

MSJ-0011

Phase 3

Anovulation

Atacicept

Phase 3

Lupus Erythematosus, Systemic

GONAL-f®

Phase 3

Infertility

Pergoveris®

Phase 3

Assisted Reproductive Techniques

Enpatoran

Phase 3

Systematic Lupus Erythematosus

Avelumab Weekly

Phase 3

First Line Non-Small Cell Lung Cancer

Recombinant Human Choriogonadotropin (r-hCG)

Phase 3

Polycystic Ovarian Syndrome

Recombinant human chorionic gonadotrophin (r-hCG)

Phase 3

Infertility

Cladribine High Dose

Phase 3

Generalized Myasthenia Gravis

Encorafenib

Phase 3

BRAF V600E

Recombinant human follicle stimulating hormone (r-hFSH)

Phase 3

Polycystic Ovarian Syndrome

5Fluorouracil

Phase 3

Metastatic Colorectal Cancer

Coriogonadotropin alfa

Phase 3

Infertility

Gonadotropin-releasing hormone (GnRH) analogue

Phase 3

Luteal Hormone Supplementation in In-vitro Fertilization

Avelumab

Phase 3

Carcinoma, Hepatocellular

Recombinant human follicle-stimulating hormone (r-hFSH)

Phase 3

Hypogonadism

RNF

Phase 3

Multiple Sclerosis

Human chorionic gonadotropin (hCG)

Phase 3

Hypogonadism

Cetrorelix acetate

Phase 3

Infertility

Rebif New Formulation + ibuprofen PRN

Phase 3

Relapsing Multiple Sclerosis

Progesterone gel

Phase 3

Infertility

Follicle-stimulating hormone (FSH)

Phase 3

Luteal Hormone Supplementation in In-vitro Fertilization

Saizen®

Phase 3

Idiopathic Short Stature

Tecemotide (L-BLP25)

Phase 3

Non-small Cell Lung Cancer

M7824

Phase 3

Non-small Cell Lung Cancer

Precemtabart tocentecan

Phase 3

Metastatic Colorectal Cancer

Saizen® B

Phase 3

Children Born With Serious Intra-uterine Growth Retardation

Docetaxel

Phase 3

Carcinoma, Non-Small-Cell Lung

Cisplatin

Phase 3

Squamous Cell Carcinoma of the Head and Neck

MSB11022

Phase 3

Psoriasis

Recombinant human chorionic gonadotropin (r-hCG)

Phase 3

Assisted Reproductive Techniques

Bisoprolol/Amlodipine (Amlodipine failed group)

Phase 3

Hypertension

Follitropin alpha

Phase 3

Anovulation

Cilengitide

Phase 3

Glioblastoma

M5049 medium dose

Phase 2

Systemic Lupus Erythematosus

Standard first line treatment with cetuximab + Folfiri

Phase 2

Colorectal Cancer

Recombinant human luteinizing hormone (r-hLH)

Phase 2

Infertility

cilengitide (5-times weekly)

Phase 2

Glioblastoma

M5049 high dose

Phase 2

Systemic Lupus Erythematosus

Interferon beta-1a (Rebif®) alone

Phase 2

Relapsing-Remitting Multiple Sclerosis

M1774

Phase 2

Non-Small Cell Lung Cancer

combination of Avelumab and Cabozantinib

Phase 2

Cancer

Curcumin

Phase 2

Multiple Sclerosis

M5717

Phase 2

Malaria Infection

Lartesertib (M4076)

Phase 2

Ovarian Cancer

r-hLH

Phase 2

Ovarian Stimulation

r-hCG

Phase 2

Ovarian Stimulation

Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)

Phase 2

Infertility Implantation Failure

Analogous GnRH antagonist

Phase 2

Ovarian Stimulation

AS900672-Enriched

Phase 2

Infertility

Follitropin alfa 150 international unit (IU)

Phase 2

Infertility

Racemate Praziquantel ODT

Phase 2

Schistosomiasis

Enpatoran high dose

Phase 2

Systemic Lupus Erythematosus

Enpatoran medium dose

Phase 2

Systemic Lupus Erythematosus

Avelumab Injection

Phase 2

Gestational Trophoblastic Neoplasias (GTN)

Levo Praziquantel ODT

Phase 2

Schistosomiasis

NKTR-255

Phase 2

Locally Advanced or Metastatic Urothelial Carcinoma

Chemotherapy + Immunotherapy Induction

Phase 2

Muscle-invasive Bladder Cancer

Immunotherapy Maintenance

Phase 2

Muscle-invasive Bladder Cancer

Cisplatin/Carboplatin

Phase 2

Squamous Cell Carcinoma of the Head and Neck

Tepotinib

Phase 2

Carcinoma, Hepatocellular

Pyronaridine

Phase 2

Acute Malaria

GEN-001

Phase 2

Gastric Cancer

M2591

Phase 2

Rheumatoid Arthritis

Peposertib

Phase 2

Locally Advanced Rectal Cancer

Pimasertib

Phase 2

Pancreatic Adenocarcinoma

Nirogacestat

Phase 2

Desmoid Tumor

Cilengitide (2-times weekly)

Phase 2

Glioblastoma

Immune Checkpoint Inhibitor

Phase 2

HCC

Mirdametinib

Phase 2

NF1

Berzosertib

Phase 2

Small-cell Lung Cancer

Nirogacestat Hydrobromide

Phase 2

Desmoid Fibromatosis

Association of berzosertib with gemcitabine

Phase 2

Leiomyosarcoma, Adult

HMBD-001

Phase 2

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

M6223

Phase 2

Locally Advanced or Metastatic Urothelial Carcinoma

M5049

Phase 2

Coronavirus Disease 2019

Tuvusertib (M1774)

Phase 2

Ovarian Cancer

Enpatoran low dose

Phase 2

Systemic Lupus Erythematosus

Atacicept: with loading dose

Phase 2

Rheumatoid Arthritis

Pembrolizumab

Phase 2

Metastatic Colorectal Cancer

FOLFOX

Phase 2

Metastatic Colorectal Cancer

Dose escalation of cetuximab

Phase 2

Colorectal Cancer

Compound 451238

Phase 2

Soft-tissue Sarcoma

M2951

Phase 2

Rheumatoid Arthritis

Vemurafenib and Cobimetinib

Phase 2

Lymphoma, Non-Hodgkin

Frequently asked questions

What is in Merck KGaA's drug pipeline?→

CatalystAlert tracks 88 drug candidates in Merck KGaA's (MKKGY) pipeline across Phase 3, Phase 2. Its lead program is Avelumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Merck KGaA's next FDA catalyst?→

Merck KGaA's (MKKGY) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track MKKGY biotech catalysts?→

Add MKKGY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Merck KGaA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply